{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:40:51Z","timestamp":1790692851397,"version":"4.1.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008779","name":"GCS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.autrev.2020.102569","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T20:03:30Z","timestamp":1588536210000},"page":"102569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"title":["Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review"],"prefix":"10.1016","volume":"19","author":[{"given":"Jaume","family":"Alijotas-Reig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Esteve-Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Belizna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Selva-O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Pardos-Gea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsene","family":"Mekinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Anunciacion-Llunell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Mir\u00f3-Mur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102569_bb0005","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102569_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102569_bb0015","first-page":"101606","article-title":"Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis Travel","volume":"27","author":"Huang","year":"2020","journal-title":"Med Infect Dis"},{"key":"10.1016\/j.autrev.2020.102569_bb0020","author":"WHO Coronavirus Disease"},{"key":"10.1016\/j.autrev.2020.102569_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102569_bb0030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","article-title":"Hemophagocytic lymphohistiocytosis","volume":"13","author":"Hanny Al-Samkari","year":"2018","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.autrev.2020.102569_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102538","article-title":"Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning","author":"Shoenfeld","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102569_bb0040","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1177\/0961203313504633","article-title":"Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS)","volume":"22","author":"Agmon-Levin","year":"2013","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.autrev.2020.102569_bb0045","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12026-014-8563-7","article-title":"sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia","volume":"60","author":"Colafrancesco","year":"2014","journal-title":"Immunol Res"},{"key":"10.1016\/j.autrev.2020.102569_bb0055","series-title":"Severe hyper-inflammatory COVID-19, another piece in the puzzle of the \u201chtperferritinemic syndrome\u201d. The rheumatologist\u2019s point of view","author":"Ruscitti","year":"2020"},{"key":"10.1016\/j.autrev.2020.102569_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102569_bb0065","first-page":"1","article-title":"Pediatric macrophage activation syndrome, recognizing the tip of the iceberg","author":"Crayne","year":"2019","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102569_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00277-018-3500-9","article-title":"Hemophagocytic syndrome in patients living with HIV: a retrospective study","volume":"98","author":"Telles","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2020.102569_bb0075","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(03)13413-7","article-title":"Lung pathology of fatal severe acute respiratory syndrome","volume":"361","author":"Nicholls","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102569_bb0080","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S0140-6736(03)13077-2","article-title":"SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102569_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102569_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2015.1.183","article-title":"The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults","author":"Nikiforow","year":"2015","journal-title":"Am Soc Hematol Educ Program"},{"key":"10.1016\/j.autrev.2020.102569_bb0100","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/1744666X.2015.1058159","article-title":"Clinical features and correct diagnosis of macrophage activation syndrome","volume":"11","author":"Cron","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"6071","key":"10.1016\/j.autrev.2020.102569_bb0105","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1126\/science.1214935","article-title":"Disease tolerance as a defense strategy","volume":"335","author":"Medzhitov","year":"2012","journal-title":"Science."},{"key":"10.1016\/j.autrev.2020.102569_bb0110","article-title":"Updated approaches against SARS -CoV \u2013 2","author":"Li","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10223","key":"10.1016\/j.autrev.2020.102569_bb0115","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102569_bb0120","article-title":"Compounds with therapeutic potential against novel 336 respiratory 2019 coronavirus","volume":"337","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.autrev.2020.102569_bb0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2020.102569_bb0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","article-title":"Is COVID-19 receiving ADE from other coronaviruses?","volume":"22","author":"Tetro","year":"2020","journal-title":"Microbes Infect"},{"issue":"3","key":"10.1016\/j.autrev.2020.102569_bb0135","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1073\/pnas.0409065102","article-title":"Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses","volume":"102","author":"Yang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2020.102569_bb0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12969-019-0309-6","article-title":"Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome","volume":"17","author":"Halyabar","year":"2019","journal-title":"Pediatric Rheumatol"},{"key":"10.1016\/j.autrev.2020.102569_bb0145","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","author":"Zhou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.autrev.2020.102569_bb0150","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"20","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.autrev.2020.102569_bb0155","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","article-title":"Chloroquine treatment influences proinflammatory cytokine level in systemic lupus erythematosus patients","volume":"15","author":"Wozniacka","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2020.102569_bb0160","series-title":"Textbook of Rheumatology","first-page":"731","article-title":"Antimalarial drugs","author":"Rynes","year":"1993"},{"key":"10.1016\/j.autrev.2020.102569_bb0165","article-title":"Clinical trial analysis of 2019-nCoV therapy registered in China","author":"Qi Zhang","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.autrev.2020.102569_bb0170","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.autrev.2020.102569_bb0175","doi-asserted-by":"crossref","first-page":"105932","DOI":"10.1016\/j.ijantimicag.2020.105932","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","volume":"4","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.autrev.2020.102569_bb0180","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2020.102569_bb0185","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/BOR.0000000000000700","article-title":"Recent advances in the diagnosis and management of giant cell arteritis","volume":"32","author":"Serling-Boyd","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102569_bb0190","author":"Drug Approval Package: ACTEMRA tocilizumab\u2013FDA"},{"key":"10.1016\/j.autrev.2020.102569_bb0195","doi-asserted-by":"crossref","DOI":"10.7326\/L20-0895","article-title":"Histopathologic Changes and SARS\u2013CoV-2 Immunostaining in the lung of a patient with COVID-19","author":"Zhang","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0200","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","author":"Xu","year":"2020","journal-title":"chinaXiv"},{"key":"10.1016\/j.autrev.2020.102569_bb0205","author":"Chinese Clinical Trial Registry"},{"key":"10.1016\/j.autrev.2020.102569_bb0210","author":"European Pharmaceutical Review Report"},{"key":"10.1016\/j.autrev.2020.102569_bb0215","first-page":"241","article-title":"Molecular differences in anticytokine therapies","volume":"21","author":"Calabrese","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2020.102569_bb0220","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/372363a0","article-title":"Functional association of cyclophilin a with HIV-1 virions","volume":"372","author":"Thali","year":"1994","journal-title":"Nature."},{"issue":"10","key":"10.1016\/j.autrev.2020.102569_bb0230","doi-asserted-by":"crossref","first-page":"e1002331","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.autrev.2020.102569_bb0235","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.autrev.2020.102569_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"On behalf of the MEDRA5 [Spanish MDA5 Register] group. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2020.102569_bb0245","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/17512433.2017.1353910","article-title":"Pharmacological management of dermatomyositis","volume":"10","author":"Griger","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.autrev.2020.102569_bb0250","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2169\/internalmedicine.1121-18","article-title":"Anti-MDA5 antibody-positive dermatomyositis complicated by autoimmune-associated Hemophagocytic syndrome that was successfully treated with immunosuppressive therapy and plasmapheresis","volume":"57","author":"Fujita","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines [IL-1 and IL-6] and lung inflammation by COVID-19: anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"issue":"10223","key":"10.1016\/j.autrev.2020.102569_bb0260","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102569_bb0265","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.autrev.2020.102569_bb0270","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2020.102569_bb0275","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune iv immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza a [H1N1] infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2020.102569_bb0280","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s10096-005-0004-z","article-title":"Treatment of severe acute respiratory syndrome","volume":"24","author":"Lai","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.autrev.2020.102569_bb0285","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/22221751.2020.1741327","article-title":"Clinical observation and management of COVID-19 patients","volume":"9","author":"Li","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.autrev.2020.102569_bb0290","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12028-015-0115-z","article-title":"Transfusion-related acute lung injury after IVIG for myasthenic crisis","volume":"23","author":"Reddy","year":"2015","journal-title":"Neurocrit Care"},{"issue":"9896","key":"10.1016\/j.autrev.2020.102569_bb0295","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S0140-6736(12)62197-7","article-title":"Transfusion-related acute lung injury: a clinical review","volume":"382","author":"Vlaar","year":"2013","journal-title":"Lancet"},{"issue":"8500","key":"10.1016\/j.autrev.2020.102569_bb0300","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(86)92511-0","article-title":"Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients","volume":"2","author":"Woodruff","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102569_bb0305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13054-020-2818-6","article-title":"Treatment of COVID-19: old tricks for new challenges","volume":"24","author":"Cunningham","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2020.102569_bb0310","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.autrev.2020.102569_bb0315","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3201\/eid2209.151164","article-title":"Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection","volume":"9","author":"Arabi","year":"2016","journal-title":"Saudi Arabia Emerg Infect Dis"},{"key":"10.1016\/j.autrev.2020.102569_bb0320","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.autrev.2020.102569_bb0325","article-title":"Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19","volume":"41","author":"Heng","year":"2020","journal-title":"Chin J Hematol"},{"key":"10.1016\/j.autrev.2020.102569_bb0330","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"95","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102569_bb0335","article-title":"SARS: system rev treat effects","volume":"9","author":"Stockman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/pgmj.2004.030049","article-title":"Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome","volume":"81","author":"Ng","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.autrev.2020.102569_bb0345","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa254","article-title":"Acute pulmonary embolism and COVID-19 pneumonia: a random association?","author":"Danzi","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.autrev.2020.102569_bb0350","article-title":"Diagnostic evaluation of pulmonary embolism during the COVID-19 pandemic","author":"Zuckier","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.autrev.2020.102569_bb0355","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/22221751.2020.1741327","article-title":"Clinical observation and management of COVID-19 patients","volume":"9","author":"Li","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.autrev.2020.102569_bb0360","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2020.102569_bb0365","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/j.thromres.2009.11.030","article-title":"Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy","volume":"125","author":"Oberkersch","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2020.102569_bb0370","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MOH.0b013e3283497f3e","article-title":"Complement and the antiphospholipid syndrome","volume":"18","author":"Lim","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.autrev.2020.102569_bb0375","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0380","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.avsg.2006.07.003","article-title":"Low molecular weight heparin suppresses tumour necrosis factor expression from deep vein thrombosis","volume":"21","author":"Carr","year":"2007","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.autrev.2020.102569_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","article-title":"Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide [fondaparinux]","volume":"109","author":"Samama","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.autrev.2020.102569_bb0390","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1177\/0961203312440347","article-title":"Circulating B2glycoprotein I-IgG anti-B2glycoprotein I immunocomplexes in patients with definite antiphospholipid syndrome","volume":"21","author":"Banzato","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2020.102569_bb0395","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunications between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102569_bb0400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/RHU.0b013e3181cf3464","article-title":"Osteonecrosis in patients after severe acute respiratory syndrome [SARS]: possible role of anticardiolipin antibodies","volume":"16","author":"Sun","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102569_bb0405","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0410","article-title":"Therapeutic mechanisms of glucocorticoids","volume":"9","author":"Vandewalle","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.autrev.2020.102569_bb0415","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2014 new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2020.102569_bb0420","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2020.102569_bb0425","first-page":"1","article-title":"Corticosteroid therapy for sepsis: a clinical practice guideline","volume":"362","author":"Lamontagne","year":"2018","journal-title":"BMJ."},{"key":"10.1016\/j.autrev.2020.102569_bb0430","series-title":"National Institute for the Infectious Diseases \u201cL. Spallanzani\u201d, IRCCS Recommendations for COVID-19 Clinical Management. Infectious disease report","first-page":"1","author":"Nicastri","year":"2020"},{"key":"10.1016\/j.autrev.2020.102569_bb0435","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-CoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102569_bb0440","series-title":"Pharmacological agents for adults with acute respiratory distress syndrome","author":"Cochrane Database Syst Rev","year":"2019"},{"key":"10.1016\/j.autrev.2020.102569_bb0445","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102569_bb0450","author":"National Health Commission & State Administration of traditional Chinese medicine"},{"key":"10.1016\/j.autrev.2020.102569_bb0455","author":"Brody"},{"key":"10.1016\/j.autrev.2020.102569_bb0460","series-title":"Clinical management of severe acute respiratory infection [SARI] when COVID-19 disease is suspected Interim guidance","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.autrev.2020.102569_bb0470","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"R. Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2020.102569_bb0475","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imay","year":"2005","journal-title":"Nature"},{"issue":"6965","key":"10.1016\/j.autrev.2020.102569_bb0480","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature."},{"key":"10.1016\/j.autrev.2020.102569_bb0485","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.lfs.2005.09.038","article-title":"Age- and gender-related difference of ACE2 expression in rat lung","volume":"78","author":"Xudong","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.autrev.2020.102569_bb0490","doi-asserted-by":"crossref","first-page":"307315","DOI":"10.1155\/2012\/307315","article-title":"Angiotensin-converting enzyme 2: the first decade","volume":"2012","author":"Clarke","year":"2012","journal-title":"Int J Hypertens"},{"key":"10.1016\/j.autrev.2020.102569_bb0495","article-title":"ACE2 at the Centre of COVID-19 from paucisymptomatic infections to severe pneumonia","author":"Felice Rivellese","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2020.102569_bb0500","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.lfs.2005.09.038","article-title":"Age- and gender-related difference of ACE2 expression in rat lung","volume":"78","author":"Xudong","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.autrev.2020.102569_bb0505","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41421-020-0147-1","article-title":"Comparative genetic analysis of the novel coronavirus [2019-nCoV\/SARS-CoV-2] receptor ACE2 in different populations","volume":"6","author":"Cao","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.autrev.2020.102569_bb0510","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS20150027","article-title":"Cellular and molecular mechanisms of statins: an update on pleiotropic effects","volume":"129","author":"Satoh","year":"2015","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.autrev.2020.102569_bb0515","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/OGX.0000000000000522","article-title":"Pravastatin for preventing and treating preeclampsia: a systematic review","volume":"73","author":"Esteve-Valverde","year":"2018","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.autrev.2020.102569_bb0520","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/infdis\/jiu474","article-title":"A practical treatment for patients with Ebola virus disease","volume":"21","author":"Fedson","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.autrev.2020.102569_bb0525","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00398-20","article-title":"Hiding in plain sight: an approach to treating patients with severe COVID-19 infection","volume":"11","author":"Fedson","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.autrev.2020.102569_bb0530","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/rccm.200810-1584OC","article-title":"Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers","volume":"179","author":"Shyamsundar","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2020.102569_bb0535","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/SHK.0b013e318189017a","article-title":"Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappa\/\u03b2 and mitogen-activated protein kinases","volume":"3","author":"Shen","year":"2009","journal-title":"Shock"},{"key":"10.1016\/j.autrev.2020.102569_bb0540","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1191\/0961203306lu2274rr","article-title":"Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity","volume":"15","author":"Shepshelovich","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2020.102569_bb0545","series-title":"Encyclopedia of life sciences","article-title":"Autoimmune diseases","author":"Volpe","year":"2001"},{"key":"10.1016\/j.autrev.2020.102569_bb0550","series-title":"Innovative medicine","first-page":"131","article-title":"IL-6: a new era for the treatment of autoimmune inflammatory diseases","author":"Kishimoto","year":"2015"},{"key":"10.1016\/j.autrev.2020.102569_bb0555","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2020.102569_bb0560","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000164056","article-title":"Expression of HLA-DR and cytokine genes on interferon-\u03b3-stimulated human salivary gland cell line","volume":"64","author":"Hamano","year":"1996","journal-title":"Pathobiology"},{"key":"10.1016\/j.autrev.2020.102569_bb0565","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cyto.2014.11.028","article-title":"Cytokines pre-determined by genetic factors are involved in pathogenesis of rheumatoid arthritis","volume":"75","author":"Taneja","year":"2015","journal-title":"Cytokine."},{"issue":"10230","key":"10.1016\/j.autrev.2020.102569_bb0570","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","volume":"395","author":"Ritchie","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.autrev.2020.102569_bb0575","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.4049\/jimmunol.140.5.1660","article-title":"Regulationof HLA-DRgene by IFN-gamma. Transcriptional and pos-transcriptional control","volume":"140","author":"Rosa","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2020.102569_bb0580","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and autoimmunity","volume":"2","author":"O\u2019Shea","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2020.102569_bb0585","series-title":"Clinical management of severe acute respiratory infection [SARI] when COVID-19 disease is suspected Interim guidance 13 March","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.autrev.2020.102569_bb0590","series-title":"Inpatient guidance for treatment of covid-19 in adults and children","year":"2020"},{"key":"10.1016\/j.autrev.2020.102569_bb0595","author":"The Australian and New Zealand Intensive Care Society [ANZICS]"},{"key":"10.1016\/j.autrev.2020.102569_bb0600","series-title":"Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 [COVID-19] Intensive Care Med","author":"Alhazzani","year":"2020"},{"issue":"April 10","key":"10.1016\/j.autrev.2020.102569_bb0605","article-title":"Compasionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.autrev.2020.102569_bb0610","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa102","article-title":"High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019","volume":"7","author":"Cao","year":"2020","journal-title":"Open Forum Infect Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:18:06Z","timestamp":1761599886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220301312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":121,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1568997220301312"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102569","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102569"}}